Home > Rheumatology > ACR 2021 > Spotlight on Rheumatoid Arthritis > Cycling JAK inhibitors shows similar effectiveness to switching to a bDMARD in difficult-to-treat RA

Cycling JAK inhibitors shows similar effectiveness to switching to a bDMARD in difficult-to-treat RA

Presented By
Dr Manuel Pombo-Suarez, Hospital Clinico Universitario de Santiago De Compostela, Spain

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ACR 2021
Trial
JAK-pot
The JAK-pot cohort study revealed that people with difficult-to-treat rheumatoid arthritis (RA) who do not have success with one Janus kinase (JAK) inhibitor could achieve success either by cycling to other JAK inhibitor medications or switching to a biologic drug. With both regimens, control of disease activity could be achieved to a similar extent. More and more JAK inhibitors are entering the therapeutic arena.* Therefore, it is possible to use a second JAK inhibitor if the first JAK inhibitor fails in patients with RA. “In real life, JAK inhibitors are being used primarily in patients who have already failed treatment with a biologic disease-modifying antirheumatic drug (bDMARD), and they have shown to be effective in these situations,” Dr Manuel Pombo-Suarez (Hospital Clinico Universitario de Santiago De Compostela, Spain) explained. “Looking at the 2020 update of the EULAR management recommendations for patients with RA who have failed a biologic DMA...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on